articleJournal of Microbiology Immunology and InfectionMar 11, 2020GOLD OA

TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib

DWDandan WuXOXuexian O. Yang

University of New Mexico · Hunan Agricultural University

PubMed
Indexed incrossrefdoajpubmed

Abstract

COVID-19 emerges as a pandemic disease with high mortality. Development of effective prevention and treatment is an urgent need. We reviewed TH17 responses in patients with SARS-CoV-2 and proposed an FDA approved JAK2 inhibitor Fedratinib for reducing mortality of patients with TH17 type immune profiles.

Citation impact

816
total citations
FWCI
64.45
Percentile
100%
References
10
Citations per year

Authors

2

Topics & keywords

Topics
Keywords
  • Cytokine storm
  • Coronavirus disease 2019 (COVID-19)
  • Medicine
  • Pandemic
  • 2019-20 coronavirus outbreak
  • Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
  • Disease
  • Immune system
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding